Compare · ORKA vs OXFD
ORKA vs OXFD
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Oxford Immunotec Global PLC (OXFD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and OXFD operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $4.89B.
- ORKA has hit the wire 6 times in the past 4 weeks while OXFD has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for OXFD).
- Company
- Oruka Therapeutics Inc.
- Oxford Immunotec Global PLC
- Price
- $71.99-2.53%
- -
- Market cap
- $4.89B
- -
- 1M return
- -26.35%
- -
- 1Y return
- +162.02%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- News (4w)
- 6
- 0
- Recent ratings
- 11
- 0
Latest ORKA
- SEC Form 4 filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)
- General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax
Latest OXFD
- SEC Form SC 13G filed by Oxford Immunotec Global PLC
- SEC Form 15-12B filed by Oxford Immunotec Global PLC
- SEC Form S-8 POS filed
- SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: R. Mark Klausner disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Patricia Randall disposed to the issuer $611,710 worth of Ordinary Shares (27,805 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Louise Janet Kidd disposed to the issuer $246,554 worth of Ordinary Shares (11,207 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: J Patrick Balthrop disposed to the issuer $177,782 worth of Ordinary Shares (8,081 units at $22.00), decreasing direct ownership by 100% to 0 units